B. longum BB536
BB536: Multifunctional Human Bifidobacteria Probiotic
Bifidobacterium longum subsp. longum BB536 (designated as BB536) is one of the most well-established, clinically effective probiotic strains that confers numerous profound beneficial effects on humans. BB536 possesses a proven track record of safety and clinical efficacy in improving gastrointestinal, immunological and infectious conditions, as demonstrated in more than 260 scientific studies (as of March 2024).
- Human-Residential Bifidobacterium
- (Isolated from healthy infant in 1969)
- Evidence-Based Safety
- (Genomic, toxicological, and clinical studies)
- Scientifically Backed Probiotics for All Age Groups
- (Supported by 280 scientific studies [as of Sep. 2024] )
- Regulatory Approved
- (Japan FOSHU status in 1996, FDA notified GRAS status for foods in 2009, FDA notified GRAS status for infants in 2019, China New Food Raw Material for use in infant and toddler foods in 2022, ANVISA approval in 2024)
- Quality Assured
- (FSSC22000, HALAL, Kosher)
- Long History of Safe Use in Food Products
- (For more than 40 years)
History of BB536
1969
BB536 Discovery: Isolated BB536 from a healthy infant
1977
Launched "Morinaga Bifidus"
1978
Launched "Morinaga Bifidus Yogurt"
1984
Received Science & Technology Minister's Prize
1987
Received Légion d'honneur (Officier) for Agriculture from France
1991
Launched "Morinaga Caldus"
1996
"Morinaga Bifidus Plain Yogurt" approved as Food for Specified Health Use (FOSHU)
2001
"Morinaga Caldus" and "Morinaga Bifidus" approved as FOSHUs
2005
Launched BB536 supplements in capsules
2009
Granted the U.S. FDA notified GRAS (Generally Recognized As Safe) status for use in food
2013
Manufacturing technology for bifidobacteria yogurt granted the Award for Acheivement in Technological Research from JSBBA
2018
Named the Most Innovative Health Ingredient at Gulfood Manufacturing Industry Excellence Awards
2019
50th anniversary of its discovery
Granted the U.S. FDA notified GRAS (Generally Recognized As Safe) status for use in infant formula
2020
Winner of NutraIngredients Asia Editors Award for Infant & Child Nutrition Initiative of the Year
2022
China New Food Raw Material for use in infant and toddler foods
2024
ANVISA approval
Health Benefits of BB536
For half a century, BB536 has been the superior Human-Residential Bifidobacteria (HRB) probiotic strain that helps people achieve optimal health from the inside out. Ingestion of BB536 can provide a consistent beneficial effect in improvement of gastrointestinal conditions, maintenance of intestinal microflora balance, regulation of immune response, anti-allergy, and protection against microbial infections. It is evidenced that BB536 acts in concert with the gut microbiota to drive a fine-tuned intestinal and immune balance.
Global Use of BB536
BB536 has gained world recognition. BB536 has been used as a functional food ingredient in various products such as milk-based drink, yogurt, infant formula, and nutritional supplements and has been marketed in over 30 countries for more than 40 years.
Regulation
Legislation can be varied by country when it comes to specific dosage and potential health claims of each strain.
Our regulatory team can help and advise you as to the appropriate individual markets permit. Morinaga Milk's global regulatory experts are located in all major regions. We are committed to deliver expert advice and practical solutions in order to optimize your company's success.